Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CVKD
DateTimeSourceHeadlineSymbolCompany
03/06/202423:00PR Newswire (US)Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
30/05/202407:27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
23/05/202423:00PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202423:00PR Newswire (US)Cadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202420:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
12/04/202406:30PR Newswire (US)Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/04/202423:00PR Newswire (US)Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsNASDAQ:CVKDCadrenal Therapeutics Inc
12/03/202400:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
12/03/202400:00PR Newswire (US)Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
06/03/202409:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
27/02/202401:00PR Newswire (US)Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
16/02/202400:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CVKDCadrenal Therapeutics Inc
13/02/202408:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
09/02/202401:00PR Newswire (US)Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialNASDAQ:CVKDCadrenal Therapeutics Inc
01/02/202401:00PR Newswire (US)Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsNASDAQ:CVKDCadrenal Therapeutics Inc
25/01/202401:00PR Newswire (US)Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
05/01/202401:00PR Newswire (US)Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
20/12/202301:00PR Newswire (US)Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetNASDAQ:CVKDCadrenal Therapeutics Inc
13/12/202301:00PR Newswire (US)Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationNASDAQ:CVKDCadrenal Therapeutics Inc
01/12/202308:15PR Newswire (US)Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:CVKDCadrenal Therapeutics Inc
10/11/202301:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
10/11/202301:00PR Newswire (US)Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
10/11/202300:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
24/10/202308:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
10/10/202307:15PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
09/09/202306:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
05/09/202322:00PR Newswire (US)Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressNASDAQ:CVKDCadrenal Therapeutics Inc
01/09/202306:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
01/09/202306:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
30/08/202322:00PR Newswire (US)Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)NASDAQ:CVKDCadrenal Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CVKD